Polymarket event: FDA approves a psychedelic for medical use in 2026

FDA approval in 2026 is the event being priced on Polymarket. The market centers on the likelihood that the US Food and Drug Administration will approve at least one psychedelic for medical use by 2026, reflecting trader expectations about future clinical, regulatory, and policy timelines. Because the question is framed as a single yes/no outcome tied to a specific year, it functions as a structured forecast on regulatory progress for psychedelic medicines rather than a discussion of any one trial or therapy.